Skip to main content
. 2013 Dec;57(12):5860–5869. doi: 10.1128/AAC.01016-13

Fig 9.

Fig 9

Oral (p.o.) in vivo efficacy of TXY436 in a mouse peritonitis model of systemic infection with MSSA 8325-4 (A) or MRSA ATCC 43300 (B). In the MSSA experiments, TXY436 and PC190723 were administered at 128 mg/kg in four divided doses. In the MRSA experiments, TXY436 was administered at 192 mg/kg in six divided doses. The vehicle was 10 mM citrate (pH 2.6) in all experiments.